SG11202106666UA - Methods for rna analysis - Google Patents

Methods for rna analysis

Info

Publication number: SG11202106666UA
Authority: SG; Singapore
Prior art keywords: methods; rna analysis; rna; analysis
Prior art date: 2018-12-21

Application number

SG11202106666UA

Inventor

Alexander Schwenger

Stefan Heinz

Tilmann Roos

Panah Benyamin Yazdan

Veronika Wagner

Original Assignee

Curevac Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-21

Filing date

2019-12-20

Publication date

2021-07-29

2019-12-20 Application filed by Curevac Ag filed Critical Curevac Ag

2021-07-29 Publication of SG11202106666UA publication Critical patent/SG11202106666UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/107—Chemical cleaving agents

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)

SG11202106666UA 2018-12-21 2019-12-20 Methods for rna analysis SG11202106666UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2018086677		2018-12-21
PCT/EP2019/086661 WO2020127959A1 (en)	2018-12-21	2019-12-20	Methods for rna analysis

Publications (1)

Publication Number	Publication Date
SG11202106666UA true SG11202106666UA (en)	2021-07-29

Family

ID=64746577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202106666UA SG11202106666UA (en)	2018-12-21	2019-12-20	Methods for rna analysis

Country Status (5)

Country	Link
US (1)	US12492425B2 (en)
EP (1)	EP3899034A1 (en)
CA (1)	CA3122645A1 (en)
SG (1)	SG11202106666UA (en)
WO (1)	WO2020127959A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012019630A1 (en)	2010-08-13	2012-02-16	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2013120499A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
AU2013242404B2 (en)	2012-03-27	2018-08-30	CureVac SE	Artificial nucleic acid molecules for improved protein or peptide expression
CN105517569A (en)	2013-08-21	2016-04-20	库瑞瓦格股份公司	Rabies vaccine
AU2014310935B2 (en)	2013-08-21	2019-11-21	CureVac SE	Combination vaccine
MX369469B (en)	2013-08-21	2019-11-08	Curevac Ag	Respiratory syncytial virus (rsv) vaccine.
EP3590529A1 (en)	2014-03-12	2020-01-08	CureVac AG	Combination of vaccination and ox40 agonists
ES2926020T3 (en)	2014-12-12	2022-10-21	Curevac Ag	Artificial Nucleic Acid Molecules for Enhanced Protein Expression
WO2016180430A1 (en)	2015-05-08	2016-11-17	Curevac Ag	Method for producing rna
CN107873055B (en)	2015-05-29	2021-09-17	库瑞瓦格房地产有限公司	Method for producing and purifying RNA comprising at least one tangential flow filtration step
US11413346B2 (en)	2015-11-09	2022-08-16	Curevac Ag	Rotavirus vaccines
CN108778308A (en)	2015-12-22	2018-11-09	库瑞瓦格股份公司	Methods of producing RNA molecule compositions
SG10201913630YA (en)	2016-02-17	2020-03-30	Curevac Ag	Zika virus vaccine
US11920174B2 (en)	2016-03-03	2024-03-05	CureVac SE	RNA analysis by total hydrolysis and quantification of released nucleosides
WO2017191274A2 (en)	2016-05-04	2017-11-09	Curevac Ag	Rna encoding a therapeutic protein
EP4631970A2 (en)	2016-05-04	2025-10-15	CureVac SE	Nucleic acid molecules and uses thereof
US11464847B2 (en)	2016-12-23	2022-10-11	Curevac Ag	Lassa virus vaccine
WO2018115527A2 (en)	2016-12-23	2018-06-28	Curevac Ag	Mers coronavirus vaccine
WO2018172556A1 (en)	2017-03-24	2018-09-27	Curevac Ag	Nucleic acids encoding crispr-associated proteins and uses thereof
WO2018211038A1 (en)	2017-05-17	2018-11-22	Curevac Ag	Method for determining at least one quality parameter of an rna sample
US11602557B2 (en)	2017-08-22	2023-03-14	Cure Vac SE	Bunyavirales vaccine
EP3707271A1 (en)	2017-11-08	2020-09-16	CureVac AG	Rna sequence adaptation
WO2019115635A1 (en)	2017-12-13	2019-06-20	Curevac Ag	Flavivirus vaccine
EP3728634A1 (en)	2017-12-21	2020-10-28	CureVac AG	Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
BR112020020933A2 (en)	2018-04-17	2021-04-06	Curevac Ag	INNOVATIVE RSV RNA MOLECULES AND VACCINATION COMPOSITIONS
JP7352581B2 (en)	2018-06-28	2023-09-28	キュアバックアールエヌエイプリンターゲーエムベーハー	Bioreactor for RNA in vitro transcription
CA3122645A1 (en)	2018-12-21	2020-06-25	Curevac Ag	Methods for rna analysis
US11241493B2 (en)	2020-02-04	2022-02-08	Curevac Ag	Coronavirus vaccine
US12194089B2 (en)	2020-02-04	2025-01-14	CureVac SE	Coronavirus vaccine
WO2022034177A1 (en) *	2020-08-12	2022-02-17	Cambridge Enterprise Limited	Method for targeted nucleic acid cleavage
CA3171051A1 (en)	2020-12-22	2022-06-30	Curevac Ag	Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US11918643B2 (en)	2020-12-22	2024-03-05	CureVac SE	RNA vaccine against SARS-CoV-2 variants
CA3170747A1 (en)	2021-01-27	2022-08-04	Moritz THRAN	Method of reducing the immunostimulatory properties of in vitro transcribed rna
US20250345524A1 (en)	2021-03-31	2025-11-13	CureVac SE	Syringes containing pharmaceutical compositions comprising rna
US20240342206A1 (en)	2021-07-30	2024-10-17	CureVac SE	mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
US20240398933A1 (en)	2021-09-03	2024-12-05	CureVac SE	Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20250099614A1 (en)	2022-01-28	2025-03-27	CureVac SE	Nucleic acid encoded transcription factor inhibitors
EP4531902A1 (en)	2022-05-25	2025-04-09	CureVac SE	Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
DE202023106198U1 (en)	2022-10-28	2024-03-21	CureVac SE	Nucleic acid-based vaccine
WO2024089229A1 (en)	2022-10-28	2024-05-02	CureVac SE	Improved formulations comprising lipid-based carriers encapsulating rna

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5594136A (en)	1989-12-21	1997-01-14	Pharmacyclics, Inc.	Texaphyrin solid supports and devices
PT1857122E (en)	2001-06-05	2011-03-07	Curevac Gmbh	Stabilised mrna with increased g/c content, coding for a viral antigen
DE10162480A1 (en)	2001-12-19	2003-08-07	Ingmar Hoerr	The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en)	2002-07-03	2004-01-29	Curevac Gmbh	Immune stimulation through chemically modified RNA
DE10335833A1 (en)	2003-08-05	2005-03-03	Curevac Gmbh	Transfection of blood cells with mRNA for immune stimulation and gene therapy
DE102004042546A1 (en)	2004-09-02	2006-03-09	Curevac Gmbh	Combination therapy for immune stimulation
DE102005023170A1 (en)	2005-05-19	2006-11-23	Curevac Gmbh	Optimized formulation for mRNA
WO2007125173A2 (en) *	2006-05-03	2007-11-08	Baltic Technology Development, Ltd.	Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
US8304529B2 (en)	2006-07-28	2012-11-06	Life Technologies Corporation	Dinucleotide MRNA cap analogs
DE102006035618A1 (en)	2006-07-31	2008-02-07	Curevac Gmbh	Nucleic acid of the formula (I): GlXmGn, in particular as immunostimulating adjuvant
DE102006061015A1 (en)	2006-12-22	2008-06-26	Curevac Gmbh	Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en)	2007-01-09	2008-07-10	Curevac Gmbh	RNA-encoded antibodies
CN104072561B (en)	2007-06-19	2017-12-22	路易斯安那州州立大学及农业机械学院管理委员会	The synthesis of the anti-reverse phosphorothioate analogs of mRNA cap and purposes
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en)	2007-10-09	2009-04-16	Curevac Gmbh	Composition for treating prostate cancer (pca)
WO2009046738A1 (en)	2007-10-09	2009-04-16	Curevac Gmbh	Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP3346005A1 (en)	2008-01-31	2018-07-11	CureVac AG	Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
PL215513B1 (en)	2008-06-06	2013-12-31	Univ Warszawski	New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2281579A1 (en)	2009-08-05	2011-02-09	BioNTech AG	Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en)	2009-12-09	2011-06-16	Curevac Gmbh	Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
ES2558106T3 (en)	2010-07-30	2016-02-02	Curevac Ag	Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
WO2012019630A1 (en)	2010-08-13	2012-02-16	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en)	2010-12-29	2012-07-05	Curevac Gmbh	Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en)	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in newborns and infants
WO2012113413A1 (en)	2011-02-21	2012-08-30	Curevac Gmbh	Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en)	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in elderly patients
US8969545B2 (en)	2011-10-18	2015-03-03	Life Technologies Corporation	Alkynyl-derivatized cap analogs, preparation and uses thereof
EP2623121A1 (en)	2012-01-31	2013-08-07	Bayer Innovation GmbH	Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113325A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120497A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
SG11201405545XA (en)	2012-03-27	2014-11-27	Curevac Gmbh	Artificial nucleic acid molecules comprising a 5'top utr
SG10201607962RA (en)	2012-03-27	2016-11-29	Curevac Ag	Artificial nucleic acid molecules
AU2013242404B2 (en)	2012-03-27	2018-08-30	CureVac SE	Artificial nucleic acid molecules for improved protein or peptide expression
EP2854857B1 (en)	2012-05-25	2018-11-28	CureVac AG	Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
ES2649180T3 (en)	2013-02-22	2018-01-10	Curevac Ag	Combination of vaccination and inhibition of the PD-1 route
PL3495505T3 (en)	2013-03-14	2025-01-13	Translate Bio, Inc.	Quantitative assessment for cap efficiency of messenger rna
EA201591283A1 (en)	2013-03-14	2016-02-29	Шир Хьюман Дженетик Терапис, Инк.	QUANTITATIVE ESTIMATION OF CEP EFFICIENCY OF MATRIX RNA
AU2014310935B2 (en)	2013-08-21	2019-11-21	CureVac SE	Combination vaccine
AU2014310932B2 (en)	2013-08-21	2019-06-06	CureVac SE	Composition and vaccine for treating lung cancer
MX369469B (en)	2013-08-21	2019-11-08	Curevac Ag	Respiratory syncytial virus (rsv) vaccine.
CN105517569A (en)	2013-08-21	2016-04-20	库瑞瓦格股份公司	Rabies vaccine
SG10201801433XA (en)	2013-08-21	2018-04-27	Curevac Ag	Composition and vaccine for treating prostate cancer
SG10201801428RA (en)	2013-08-21	2018-03-28	Curevac Ag	Method for increasing expression of rna-encoded proteins
CA2925021C (en)	2013-11-01	2025-05-06	Curevac Ag	Modified rna with decreased immunostimulatory properties
SG11201604198YA (en)	2013-12-30	2016-07-28	Curevac Ag	Methods for rna analysis
WO2015101415A1 (en)	2013-12-30	2015-07-09	Curevac Gmbh	Artificial nucleic acid molecules
CN111304231A (en)	2013-12-30	2020-06-19	库瑞瓦格股份公司	artificial nucleic acid molecules
EP3590529A1 (en)	2014-03-12	2020-01-08	CureVac AG	Combination of vaccination and ox40 agonists
EP3129050A2 (en)	2014-04-01	2017-02-15	CureVac AG	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
EP3155129B1 (en)	2014-06-10	2019-01-16	CureVac AG	Method for enhancing rna production
ES2926020T3 (en)	2014-12-12	2022-10-21	Curevac Ag	Artificial Nucleic Acid Molecules for Enhanced Protein Expression
CA2962849A1 (en)	2014-12-16	2016-06-23	Curevac Ag	Ebolavirus and marburgvirus vaccines
EP3240558A1 (en)	2014-12-30	2017-11-08	CureVac AG	Artificial nucleic acid molecules
WO2016165825A1 (en)	2015-04-13	2016-10-20	Curevac Ag	Method for producing rna compositions
EP4026568A1 (en)	2015-04-17	2022-07-13	CureVac Real Estate GmbH	Lyophilization of rna
JP6912384B2 (en)	2015-04-22	2021-08-04	キュアバックアーゲー	RNA-containing compositions for the treatment of cancer diseases
US20180208957A1 (en)	2015-04-30	2018-07-26	Curevac Ag	Method for in vitro transcription using an immobilized restriction enzyme
SG11201708867UA (en)	2015-04-30	2017-11-29	Curevac Ag	Immobilized poly(n)polymerase
WO2016180430A1 (en)	2015-05-08	2016-11-17	Curevac Ag	Method for producing rna
AU2016264027A1 (en)	2015-05-15	2017-08-31	Curevac Ag	Prime-boost regimens involving administration of at least one mRNA construct
US10729654B2 (en)	2015-05-20	2020-08-04	Curevac Ag	Dry powder composition comprising long-chain RNA
WO2016184575A1 (en)	2015-05-20	2016-11-24	Curevac Ag	Dry powder composition comprising long-chain rna
US11608513B2 (en)	2015-05-29	2023-03-21	CureVac SE	Method for adding cap structures to RNA using immobilized enzymes
CN107873055B (en)	2015-05-29	2021-09-17	库瑞瓦格房地产有限公司	Method for producing and purifying RNA comprising at least one tangential flow filtration step
EP3310384A1 (en)	2015-06-17	2018-04-25	CureVac AG	Vaccine composition
EP3317424B1 (en)	2015-07-01	2023-09-06	CureVac Manufacturing GmbH	Method for analysis of an rna molecule
US10501768B2 (en)	2015-07-13	2019-12-10	Curevac Ag	Method of producing RNA from circular DNA and corresponding template DNA
US20200085852A1 (en)	2015-08-05	2020-03-19	Curevac Ag	Epidermal mrna vaccine
EP3699288A1 (en)	2015-08-07	2020-08-26	CureVac AG	Process for the in vivo production of rna in a host cell
EP4155409B1 (en)	2015-08-10	2023-12-27	CureVac Manufacturing GmbH	Method of increasing the replication of a circular dna molecule
US12258567B2 (en)	2015-08-28	2025-03-25	CureVac SE	Artificial nucleic acid molecules
HUE065704T2 (en)	2015-09-21	2024-06-28	Trilink Biotechnologies Llc	Compositions and methods for synthesizing 5 -capped rnas
US11225682B2 (en)	2015-10-12	2022-01-18	Curevac Ag	Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066797A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Trinucleotide mrna cap analogs
WO2017066791A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Sugar substituted mrna cap analogs
AU2016340183A1 (en)	2015-10-16	2018-04-19	Modernatx, Inc.	mRNA cap analogs and methods of mRNA capping
WO2017066789A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Mrna cap analogs with modified sugar
DK3362461T3 (en)	2015-10-16	2022-05-09	Modernatx Inc	MRNA-CAP ANALOGS WITH MODIFIED PHOSPHAT BINDING
WO2017066782A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Hydrophobic mrna cap analogs
US11413346B2 (en)	2015-11-09	2022-08-16	Curevac Ag	Rotavirus vaccines
EP3374504B1 (en)	2015-11-09	2025-03-19	CureVac SE	Optimized nucleic acid molecules
EP3387150B1 (en)	2015-12-09	2019-10-02	Novartis AG	Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
US20180371392A1 (en)	2015-12-21	2018-12-27	Curevac Ag	Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
CN108778308A (en)	2015-12-22	2018-11-09	库瑞瓦格股份公司	Methods of producing RNA molecule compositions
US11248223B2 (en)	2015-12-23	2022-02-15	Curevac Ag	Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
EP4289965A3 (en)	2016-02-12	2024-02-21	CureVac SE	Method for analyzing rna
US20190049414A1 (en)	2016-02-15	2019-02-14	Curevac Ag	Method for analyzing by-products of rna in vitro transcription
SG10201913630YA (en)	2016-02-17	2020-03-30	Curevac Ag	Zika virus vaccine
US11920174B2 (en)	2016-03-03	2024-03-05	CureVac SE	RNA analysis by total hydrolysis and quantification of released nucleosides
US20190177714A1 (en)	2016-03-24	2019-06-13	Curevac Ag	Immobilized inorganic pyrophosphatase (ppase)
WO2017182634A1 (en)	2016-04-22	2017-10-26	Curevac Ag	Rna encoding a tumor antigen
US11596699B2 (en)	2016-04-29	2023-03-07	CureVac SE	RNA encoding an antibody
US20180126003A1 (en)	2016-05-04	2018-05-10	Curevac Ag	New targets for rna therapeutics
WO2017191274A2 (en)	2016-05-04	2017-11-09	Curevac Ag	Rna encoding a therapeutic protein
EP4631970A2 (en)	2016-05-04	2025-10-15	CureVac SE	Nucleic acid molecules and uses thereof
EP3464619A1 (en)	2016-05-25	2019-04-10	CureVac AG	Novel biomarkers
EP3468612A1 (en)	2016-06-09	2019-04-17	CureVac AG	Hybrid carriers for nucleic acid cargo
EP3468608A1 (en)	2016-06-09	2019-04-17	CureVac AG	Hybrid carriers for nucleic acid cargo
EP3468613A1 (en)	2016-06-09	2019-04-17	CureVac AG	Hybrid carriers for nucleic acid cargo
US20190336608A1 (en)	2016-06-09	2019-11-07	Curevac Ag	Cationic carriers for nucleic acid delivery
CN109715205A (en)	2016-08-19	2019-05-03	库瑞瓦格股份公司	RNA use for cancer treatment
WO2018075827A1 (en)	2016-10-19	2018-04-26	Arcturus Therapeutics, Inc.	Trinucleotide mrna cap analogs
IL317855A (en)	2016-10-26	2025-02-01	Acuitas Therapeutics Inc	Lipid nanoparticle mrna vaccines
US11279923B2 (en)	2016-11-28	2022-03-22	Curevac Ag	Method for purifying RNA
JP2020501545A (en)	2016-12-08	2020-01-23	キュアバックアーゲー	RNA for treatment or prevention of liver disease
US11542490B2 (en)	2016-12-08	2023-01-03	CureVac SE	RNAs for wound healing
WO2018115507A2 (en)	2016-12-23	2018-06-28	Curevac Ag	Henipavirus vaccine
US11464847B2 (en)	2016-12-23	2022-10-11	Curevac Ag	Lassa virus vaccine
WO2018115527A2 (en)	2016-12-23	2018-06-28	Curevac Ag	Mers coronavirus vaccine
CA3050614A1 (en)	2017-03-17	2018-09-20	Curevac Ag	Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2018172556A1 (en)	2017-03-24	2018-09-27	Curevac Ag	Nucleic acids encoding crispr-associated proteins and uses thereof
WO2018211038A1 (en)	2017-05-17	2018-11-22	Curevac Ag	Method for determining at least one quality parameter of an rna sample
AU2018298422B2 (en)	2017-07-04	2023-04-06	CureVac SE	Novel nucleic acid molecules
US11602557B2 (en)	2017-08-22	2023-03-14	Cure Vac SE	Bunyavirales vaccine
IL321714A (en)	2017-10-19	2025-08-01	CureVac SE	Artificial nucleic acid molecules
EP3707271A1 (en)	2017-11-08	2020-09-16	CureVac AG	Rna sequence adaptation
WO2019115635A1 (en)	2017-12-13	2019-06-20	Curevac Ag	Flavivirus vaccine
EP3728634A1 (en)	2017-12-21	2020-10-28	CureVac AG	Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
US20210361761A1 (en)	2018-04-05	2021-11-25	Curevac Ag	Novel yellow fever nucleic acid molecules for vaccination
BR112020020933A2 (en)	2018-04-17	2021-04-06	Curevac Ag	INNOVATIVE RSV RNA MOLECULES AND VACCINATION COMPOSITIONS
WO2020002525A1 (en)	2018-06-27	2020-01-02	Curevac Ag	Novel lassa virus rna molecules and compositions for vaccination
JP7352581B2 (en)	2018-06-28	2023-09-28	キュアバックアールエヌエイプリンターゲーエムベーハー	Bioreactor for RNA in vitro transcription
TW202039534A (en)	2018-12-14	2020-11-01	美商美國禮來大藥廠	Kras variant mrna molecules
US20220040281A1 (en)	2018-12-21	2022-02-10	Curevac Ag	Rna for malaria vaccines
CA3122645A1 (en)	2018-12-21	2020-06-25	Curevac Ag	Methods for rna analysis
EP3920950A1 (en)	2019-02-08	2021-12-15	CureVac AG	Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
WO2020254535A1 (en)	2019-06-18	2020-12-24	Curevac Ag	Rotavirus mrna vaccine
CA3144902A1 (en)	2019-08-14	2022-01-19	Andreas Thess	Rna combinations and compositions with decreased immunostimulatory properties
EP4076647A1 (en)	2019-12-20	2022-10-26	CureVac AG	Lipid nanoparticles for delivery of nucleic acids
US11241493B2 (en)	2020-02-04	2022-02-08	Curevac Ag	Coronavirus vaccine
JP2023530229A (en)	2020-05-29	2023-07-14	キュアバックエスイー	Nucleic acid-based combination vaccine
WO2021254593A1 (en)	2020-06-15	2021-12-23	Curevac Ag	Analysis of nucleic acid mixtures
WO2022023559A1 (en)	2020-07-31	2022-02-03	Curevac Ag	Nucleic acid encoded antibody mixtures
EP4157344A2 (en)	2020-08-31	2023-04-05	CureVac SE	Multivalent nucleic acid based coronavirus vaccines
WO2022049093A1 (en)	2020-09-01	2022-03-10	CureVac RNA Printer GmbH	Manufacturing device for a pharmaceutical product

2019
- 2019-12-20 CA CA3122645A patent/CA3122645A1/en active Pending
- 2019-12-20 US US17/416,681 patent/US12492425B2/en active Active
- 2019-12-20 EP EP19827744.4A patent/EP3899034A1/en active Pending
- 2019-12-20 SG SG11202106666UA patent/SG11202106666UA/en unknown
- 2019-12-20 WO PCT/EP2019/086661 patent/WO2020127959A1/en not_active Ceased

Also Published As

Publication number	Publication date
US12492425B2 (en)	2025-12-09
EP3899034A1 (en)	2021-10-27
US20220073962A1 (en)	2022-03-10
CA3122645A1 (en)	2020-06-25
WO2020127959A1 (en)	2020-06-25

Publication	Publication Date	Title
SG11202106666UA (en)	2021-07-29	Methods for rna analysis
IL294121A (en)	2022-08-01	Analyzing rna for diagnosing infection type
GB201706572D0 (en)	2017-06-07	Methods for colorimetric analysis
HUE072096T2 (en)	2025-10-28	Methods for chromatography data analysis
SG10201913820TA (en)	2020-03-30	Nucleic Acid Analysis Apparatus
SG10201601097XA (en)	2016-09-29	Amplitude-versus-angle analysis for quantitative interpretation
LT3119886T (en)	2017-11-10	Copy number preserving rna analysis method
GB201907242D0 (en)	2019-07-03	Dna methods etc ii
IL268209A (en)	2019-09-26	Methods for identifying and using small rna predictors
IL275910A (en)	2020-08-31	Methods for analyzing viral nucleic acid
GB201821206D0 (en)	2019-02-06	Analytical methods
SG11202108563QA (en)	2021-09-29	Methods for nucleic acid analysis
IL277890B (en)	2020-11-30	Methods for quantifying il-33
SG11202103186SA (en)	2021-04-29	Analysis system
IL268330A (en)	2019-09-26	Methods for determining interaction between biological cells
GB201717445D0 (en)	2017-12-06	Method for determining nucleotide sequence
GB2570742B (en)	2020-10-28	Optical-interference analysis
SG11202106810UA (en)	2021-07-29	Methods for targeted complementary dna enrichment
EP3296745A4 (en)	2019-01-02	Simultaneous analysis method for multiple targets using multiple metal nano-tags
PL3653731T3 (en)	2024-04-08	Method for performing genotyping analysis
GB201815111D0 (en)	2018-10-31	Analysis method
GB201910777D0 (en)	2019-09-11	Analytical method
SG11202009797UA (en)	2020-11-27	Analysis system
GB201818024D0 (en)	2018-12-19	Genomic analysis
SG11202112704TA (en)	2021-12-30	Nucleic acid analysis